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Plasma Cyclic Nucleotide Levels in Acute Leukemia Patients
Blood, Vol 69, No 6 (June), 1987: pp 1613-1616 1613
By Maddalena Peracchi, Vincenzo Toschi, Fabrizia Bamonti-Catena, Luigia Lombardi, Beatrice Bareggi,
Agostino Cortelezzi, Mariangela Colombi, Anna T. Maiolo, and Elio E. Polli
To verify the clinical usefulness of extracellular cyclic
nucleotide determination as a tumor marker. plasma cyclic
AMP (cAMP) and cyclic GMP (cGMP) levels were measured
in 70 normal subjects and i 73 acute leukemia patients
studied in different stages of their disease. Mean plasma
cAMP levels were similar in leukemic and normal subjects.
although in 48 patients in the active stage of the disease.
first diagnosis. or relapse. the cAMP values were below the
C YCLIC ADENOSINE 3’,5’-monophosphate (cAMP)
and cyclic guanosine 3’,5’-monophosphate (cGMP)
have complex and perhaps opposite regulatory influences on
proliferative processes, but their role in the pathogenesis of
malignant transformation is still unclear.”3 Alterations in the
cyclic nucleotide metabolism have often been found in neo-
plastic tissue, however, although a consistent pattern of
changes has not emenged.4’#{176}
Recently, more attention has been paid to the alterations
in extracellular cyclic nucleotide concentrations in human
malignancies due to their potential clinical usefulness as
tumor markers. Plasma and urine cAMP levels are generally
unchanged in nonmocalcemic cancer patients, however,
although increased on decreased cyclic nucleotide levels have
also been reported.9”2’ On the other hand, increased cGMP
levels and reduced cAMP/cGMP molar ratios in plasma and
urine seem to be a more constant feature of cancer patients,
with a relatively low frequency of false-negative values in the
properly controlled studies.9” l,12.14.I5.l7.21 Furthermore, our
preliminary data and those of other researchers demon-
strated that changes in cGMP levels and in cAMP/cGMP
molar ratios correlated with the patients’ response to treat-
ment and with the occurrence ofa relapse.’82’
We report here the results of a 3-year study performed to
evaluate the clinical usefulness of plasma cAMP and cGMP
level determinations in monitoring acute leukemia patients
during the different stages of their disease.
MATERIALS AND METHODS
Plasma cyclic nucleotide levels were measured in 70 healthy
volunteers, 30 males and 40 females, aged I 8 to 78 years, (mean 34.3
years) and in 173 acute leukemia patients, 103 males and 70
females, aged I 2 to 9 1 years (mean 37.9 years). The leukemia group
consisted of I I 3 recently diagnosed and untreated patients, 54 with
acute lymphoblastic leukemia (ALL) and 59 with acute nonlympho-
blastic leukemia (ANLL), and of6O treated patients, 28 with ALL
and 32 with ANLL, who were in complete remission. Plasma cyclic
nucleotide levels were subsequently reevaluated in 52 of the recently
diagnosed patients, 26 with ALL and 26 with ANLL, after they had
attained complete remission, and in 66 patients, 30 with ALL and 36
with ANLL, who relapsed. In addition, plasma cyclic nucleotide
levels were monitored monthly during chemotherapy in 18 ALL and
22 ANLL patients who eventually relapsed and in 57 patients, 28
with ALL and 29 with ANLL, who remained in complete remission
over the I 2- to 36-month period of the study. Cyclic nucleotide levels
were also measured in both plasma and CSF of eight patients, five
with ALL and three with ANLL, with an isolated leukemic involve-
ment of CNS. The control group consisted of six ALL and five
ANLL patients in complete remission without any evidence of CNS
normal range. and most of these patients failed to respond
to chemotherapy. Plasma cGMP levels were markedly
elevated in untreated patients. normalized in all patients
who attained complete remission. and increased promptly
to pretreatment values in patients who relapsed. suggest-
ing that their determination may be useful to monitor the
patients response to treatment.
a 1987 by Grune & Stratton, Inc.
leukemia, who had previously received prophylactic CNS therapy,
and who underwent lumbar puncture as a part of the procedures to
evaluate the possibility of stopping chemotherapy. All patients gave
their informed consent to the lumbar puncture.
All patients had normal serum creatinine and blood calcium
levels. Subjects were asked not to take any drug during the 2 days
before sampling, even though in a preliminary study there was no
evidence that the most common antileukemic drugs given the day
before influenced plasma cyclic nucleotide levels. All subjects were
on unrestricted activity and diet except for coffee, tea, alcohol, and
smoking, which were not allowed on the day before sampling.
Venous blood samples were drawn between 8 and 9 AM, after an
overnight fast and at least 1 hour’s rest. CSF samples were obtained
by lumbar puncture. The samples were added to prechilled tubes
containing EDTA to give a final concentration of 5 mmol/L,
immediately centrifuged at 4#{176}C,and plasma and CSF were sepa-
rated and stored at -80#{176}Cuntil assayed.
cAMP was measured by a protein binding assay and cGMP by
radioimmunoassay (RIA) using commercially available kits (Cyclic
AMP Assay Kit, Code TRK 432, and Cyclic GMP RIA Kit, Code
500; Radiochemical Centre, Amersham, England). Before being
assayed for cyclic nucleotides, plasma and CSF were extracted with
ethanol.22 All samples were tested in triplicate using at least two
different dilutions. The intra- and interassay coefficients of variation
were < 10% for both cAMP and cGMP.
Statistical significance of the data was evaluated by one-way
analysis of variance using Duncan’s and Kramer’s tests for multiple
comparisons.
RESULTS
Table I shows mean plasma cyclic nucleotide levels in the
normal subjects and in the acute leukemia patients studied in
different stages of their disease. There were no age- or
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Table 1 . Plasma Cyclic Nucleotide Levels in Acute Leukemia Patients Studi ed in Different Stages o f Their Disease
CAMP
Diagnosis Cases (n) (pmol/mL)
cGMP
(pmol/mL) CAMP/CGMP
Normal 70 i4.33±0.389
ALLfirstdiagnosis 54 12.63±0.564
ALL complete remission 54 i4.70 ± 0.405
ALLrelapse 30 12.21 ±0.821
ANLLfirstdiagnosis 59 14.12 ± 0.581
ANLL complete remission 58 14.59 ± 0.393
ANLLrelapse 36 12.03 ± 0.621
4.11 ±0.093
11.60± 1.622’
3.69 ± 0.1 i4f
8.68± i.232
13.64 ± i.970
3.73 ± 0.086t
9.96 ± 2.i03
3.56 ±0.108
i.5i ±0.ii8
4.i2 ± 0.i32t
i.8O±0.i40
1.52 ± 0.095
4.00 ± 0.i29t
1.76 ± 0.i32
Abbreviations: ALL. acute lymphoblastic leukemia; ANLL, acute nonlymphoblastic leukemia.
Data are expressed as mean ± SE.
.P < .Oi vnormal (Kramer’s test).
tP < .0 i V first diagnosis and NS v normal (Kramer’s test).
P < .05 V complete remission and NS v first diagnosis (Kramer’s test).
§P < .0 1 V complete remission and NS v first diagnosis (Kramer’s test).
sex-related differences in the cyclic nucleotide values in any
group of subjects. Leukemic patients showed mean plasma
cAMP levels similar to those of normal subjects, independent
of the stage of the disease. Plasma cAMP levels were below
the normal range (9.70 to 29.35 pmol/mL), however, in 25
recently diagnosed patients, 13 with ALL and 12 with
ANLL, and in 23 patients in relapse, I I with ALL and 12
with ANLL. On the other hand, in untreated acute leukemia
patients plasma cGMP levels were significantly higher, and
cAMP/cGMP molar ratios were significantly lower than
those of the normal subjects. Plasma cGMP levels were
above the normal range (2.42 to 5.92 pmol/mL) in 45 of 54
ALL and 48 of 59 ANLL patients, and cAMP/cGMP molar
ratios were below the normal range (2.21 to 7.04) in 48 of 54
ALL and 52 of 59 ANLL patients. As previously
reported,’8’2’ chemotherapy per se did not influence plasma
cyclic nucleotide levels, but plasma cGMP levels and
cAMP/cGMP ratios became normal in all patients who
attained complete remission and remained in the normal
range during all the remission period (Fig 1). In patients who
relapsed, plasma cGMP levels increased and cAMP/cGMP
ratios decreased to the pretreatment values (Table 1 ). Figure
2, which illustrates the plasma cyclic nucleotide pattern in 40
periodically monitored patients who relapsed under mainte-
nance therapy, shows that most patients evidenced changes
in cGMP levels and in cAMP/cGMP ratios before bone
marrow blast invasion was observed. Table 2 shows the main
hematological findings of these 40 patients during the 4
months before the relapse. There were no apparent correla-
tions between these data and changes in cyclic nucleotide
plasma levels, though platelet count was <100,000/jsL in
four ANLL patients I month before relapse.
In patients in the active stages of the disease, first
diagnosis, on relapse, plasma cGMP levels and cAMP/
cGMP ratios did not correlate with the ability to respond to
treatment, remission duration, or survival time. Plasma
cAMP levels were below the normal range in I 8 of 57
recently diagnosed and 19 of42 relapsing patients who failed
to respond to chemotherapy, however, but only in I I of the
remaining 80 responsive patients (chi-square(1) = 12.583;
P< .001).
Patients in complete remission had CSF cyclic nucleotide
levels ranging from 9.95 to 20.62 pmol/mL for cAMP and
from 2.79 to 4.89 pmol/mL for cGMP. These values were in
M 0 N I N S
Fig 1 . Plasma cyclic nucleotide levels in 57 treated acute leukemia patients who remained in complete remission. Of the patients with
acute lymphoblastic leukemia (ALL). 1 3 were monitored for 3 years. 20 for 2 years. and 28 for 1 year; of the patients with acute
nonlymphoblastic leukemia (ANLI). 1 0 were monitored for 3 years. 1 9 for 2 years. and 29 for 1 year. These numbers are shown in brackets.
Data are expressed as mean ± SE.
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Fig 2. Plasma cyclic nucleotide levels in 18 acute lymphoblas-
tic leukemia (ALL) and 22 acute nonlymphoblastic leukemia (ANLL)
patients who relapsed under treatment. Reference time is that of
relapse. Data are expressed as mean ± SE. P < .01 v findings at
-4 and -3 months (Duncan’s test). tP < .05 v findings at -4 and
- 3 months (Duncan’s test).
general agreement with those reported in the literature for
subjects without evidence of CNS disease.23’24 Patients with
isolated CNS leukemia showed mean plasma and CSF cyclic
nucleotide levels similar to those of the control subjects, with
the exception of one ALL patient, with a symptomatic
leukemic meningitis, who had CSF cGMP levels of I 1.14
pmol/mL.
DISCUSSION
There were no significant differences in plasma cyclic
nucleotide patterns between ALL and ANLL patients. Our
results, however, indicate that in acute leukemias plasma
cGMP levels and cAMP/cGMP molar ratios may be useful
to monitor the patient’s response to systemic chemotherapy
and the occurrence of medullary relapse. On the other hand,
plasma and CSF cyclic nucleotide levels were similar in
6 patients with and without CNS leukemia, indicating that
their determination does not have a role in the early diagnosis
; of CNS involvement.
!;‘ Elevations in cGMP levels and reductions in cAMP/
4  cGMP molar ratios in plasma and urine often occur in
hematological 9214I 5.20.21 and in solid tumors,”
I5.I7.9.21 although the frequency of normal values varies in the
different studies. In our patients in the active stages of
T leukemia, first diagnosis, on relapse, the frequency of false-
2  negative results was low, < I 5%, when either cGMP levels or
cAMP/cGMP ratios were considered. The reduced cAMP/
cGMP ratios generally reflected an increase in plasma
cGMP levels; in -20% of the patients, however, they were
0 due to plasma cAMP levels below the normal range. In
agreement with previously reported data indicating that
decreased extracellular cAMP levels are not a frequent
feature of normocalcemic cancer patients,9”2’ in this study
only 48 patients had markedly reduced plasma cAMP levels;
this finding, however, was an unfavorable prognostic mdi-
cator since most of these patients failed to respond to
chemotherapy.
Because changes in extracellular cyclic nucleotide levels
occur in different malignant diseases, they are not specific
for leukemias and the mechanisms governing their develop-
ment are still unclear. Extracellular cyclic nucleotide con-
centrations may reflect changes in their intracellular metab-
olism, since both adenylate cyclase-cAMP and guanylate
cyclase-cGMP systems are unbalanced in human leukemic
leukocytes,8”0 Certainly, an enhanced egress of cGMP from
cells’5 could account for the increased plasma cyclic nucleo-
tide levels we found in the active stages of acute leukemias,
though no direct evidence shows that cGMP is released from
leukemic leukocytes rather than from normal tissues as a
reaction to the malignant process. On the other hand, it
seems unlikely that a reduction in cAMP levels in leukemic
cells may in itself influence the plasma cyclic nucleotide
concentrations, due to the many factors known to affect
extracellular cAMP levels.
Studies in cancer-bearing animals have demonstrated that
Table 2. Main Hemato logical Data in 18 ALL and 22 ANLL Patients Who Relapsed Un der Mainte nance Therapy
ALL ANLL
Months
Before
Peripheral Blood Bone Marrow Peripheral Blood Bone Marrow
Hb WBC Platelets Blasts cenul&ir4 Hb WBC Platelets Blasts Cellularity
Relapse (g/dL) ( x 1 0’/L) I x 109/L) (%) I N I (g/dL) I x 109/L) I x 1 09/L) (%) I N I
-4 13.9 5.0 258 3.00 6 7 5 12.9 4.6 245 4.25 6 15 1
(9.4-. 16. 1) (3.0- 12.6) (1 10-450) (1 .25-6.00) (10. 1 - 15.5) (1 .8- 10.5) (89-608) (1.25-6.75)
-3 13.9 4.5 259 12.8 4.9 258
(9.1-15.7) (1.8-26.0) (91-609) (10.9-15.4) (2.9-9.1) (104-817)
-2 13.8 4.7 240 2.75 6 8 4 13.0 4.6 275 4.75 8 9 5
(10.5- 16.6) (3. 1 - 15.8) (105-731) (0.25-7.25) (9.8- 1 5.5) (1 .7-9.4) (95-658) (2.00- 1 1.50)
-1 14.1 4.1 204 13.0 3.7 206
(9. 1 - 16.8) (2.2-15.0) (125-429) (10.7- 16.0) (1.8- 10.9) (16-552)
0 13.5 5.4 134 38.0 6 5 7 12.4 3.2 152 26.0 10 7 5
(10.3-16.9) (1.2-21.7) (6-350) (10.0-67.0) (6.5-15.5) (0.8-17.0) (12-408) (10.0-89.0)
Data are expressed as median and range for peripheral blood and bone marrow blasts.
N  , Hypocellular, N , normocellular, I hypercellular; the numbers under this heading refer to the number of marrows with the indicated level of
cellularity.
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extnacellular cGMP levels correlate with tumor size.25’26 A an unequivocal indication of the existence of a malignant
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